Children's Hospital is part of the UPMC family.
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Ranked #8 Nationally by U.S. News & World Report.
This multicenter trial by the Children’s Oncology Group is studying how well combination chemotherapy works in treating young patients with newly diagnosed high-risk B-precursor acute lymphoblastic leukemia (HR B-ALL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
Subject to certain exclusion criteria, this study is open to males and females, ages 1 to 30 years, who have newly diagnosed HR B-ALL. Enrollees must also be enrolled in AALL08B1, an ALL classification study, prior to enrollment in this study.
Males and Females: Ages 1 to 30 years
Study participants will be tested to determine whether they have high-risk or very-high-risk B-ALL during the 4-week induction phase, which consists of a combination of oral, intravenous and intrathecal (IT) chemotherapy treatments over a course of 56 days. Following induction, high-risk participants are randomly assigned to one of two treatment arms for nearly 8 months of consolidation therapy, interim maintenance therapy and delayed intensification therapy, followed by maintenance therapy that repeats 12-week courses for 2 years for females and 3 years for males.
Very-high-risk patients are randomized into two treatment arms, for consolidation, interim maintenance, delayed intensification and maintenance therapy in courses that follow a similar timetable as the high-risk patients. One of the treatment arms introduces the drugs cyclophosphamide and etoposide.
Visits: Varies from daily to weekly to monthly depending on the treatment arm and stage of treatment.
Duration: Approximately 2 years and 8 months for female participants; 3 years 8 months for males, with patients followed for about 10 years.
Children’s Oncology Group (AALL1131)
National Cancer Institute
Study Description at National Institutes of Health
Kim Ritchey, MD
For more information about the study or enrollment, please contact:
Research Coordinator Angela Connelly, RN, BSN
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to make a donation online.